Hepatitis C Diagnosis Explained by a UK Consultant Microbiologist
Hepatitis C is often a silent infection until the point at which it has already caused liver fibrosis, cirrhosis, or hepatocellular carcinoma. The diagnostic task is not simply to “test for hepatitis C”. It is to answer a precise clinical question: has this person ever been exposed, and do they have current viraemic infection that needs treatment or public health action?
That distinction matters. An anti-HCV antibody result alone cannot diagnose active infection. A detectable HCV RNA result can.
Modern direct-acting antivirals cure most treated patients, usually with short oral regimens. That has changed the value of diagnosis. A positive result is no longer mainly a prognostic label. It is a route into curative therapy, harm reduction, contact assessment, and liver disease staging.
This article is written from a UK diagnostic microbiology perspective. Local pathways vary, so use it as an expert overview rather than a substitute for local laboratory protocols, UKHSA guidance, NICE guidance, or specialist clinical advice.
Diagnosis starts with the clinical question
Most requests arrive in the laboratory under one of four scenarios:
Screening in someone with risk factors
Investigation of abnormal liver function tests
Assessment after a recent exposure
Follow-up of a previously positive antibody or treated infection
The correct interpretation depends on which scenario applies.
Common UK testing indications include:
Current or previous injecting drug use, even once
Birth or medical care in a country with higher HCV prevalence
Blood transfusion or blood products before effective screening was introduced
Haemodialysis or renal replacement therapy
HIV infection
Sexual exposure with higher risk, especially in networks with known HCV transmission
Prison history
Needlestick or sharps injury
Children born to mothers with active HCV infection
Unexplained raised ALT or chronic liver disease
Normal liver enzymes do not exclude infection. ALT may fluctuate and can be normal in chronic hepatitis C. Conversely, mildly abnormal transaminases are common and non-specific, so serology and nucleic acid testing remain the diagnostic backbone.
In practice, Hepatitis C Diagnosis should usually proceed in two linked steps: antibody testing followed by RNA testing when indicated.
The first-line test is anti-HCV antibody
The usual screening test is an anti-HCV antibody immunoassay performed on serum or plasma. Most UK laboratories use high-throughput automated assays such as chemiluminescent or enzyme immunoassays.
A reactive antibody result means the immune system has recognised HCV at some point. It does not prove current infection.
A reactive anti-HCV can represent:
Current chronic HCV infection
Recent acute infection
Past infection with spontaneous clearance
Past infection successfully treated
A false reactive result, particularly in lower-prevalence settings
A non-reactive anti-HCV usually makes established infection unlikely, but there are exceptions.
Antibody may be negative in:
Very early acute infection, before seroconversion
Severe immunosuppression
Advanced HIV with poor immune reconstitution
Haemodialysis patients, rarely
Infants, where maternal antibody complicates interpretation
The window period is clinically important. HCV RNA becomes detectable before antibody. Antibody seroconversion often takes several weeks. If the exposure was recent, a negative antibody test is not enough to close the case.
HCV RNA confirms current infection
HCV RNA testing detects viral nucleic acid and answers the key question: is the patient viraemic now?
A detectable HCV RNA result supports current infection. In the right clinical context, it confirms active HCV and should trigger referral or linkage to treatment, liver assessment, and public health measures.
An undetectable HCV RNA result after a reactive antibody usually means one of the following:
Past resolved infection
Successful previous treatment
Intermittent low-level viraemia, uncommon but relevant in early acute infection
A false reactive antibody screening result
Many UK laboratories now use reflex testing, where a reactive antibody automatically triggers HCV RNA on the same sample if sufficient volume is available. Reflex testing reduces missed follow-up, shortens time to diagnosis, and avoids the common problem of patients not returning for repeat phlebotomy.
For clinicians, the practical message is simple: when requesting tests, make sure the pathway will identify viraemic infection, not just historical exposure. This is the point at which HCV diagnosis succeeds or fails at service level.
Anti-HCV and RNA results need paired interpretation
The following table gives a practical interpretation framework. Local reports may use different wording, but the principles are consistent.
Anti-HCV antibody | HCV RNA | Likely interpretation | Practical next step |
Negative | Not tested | No serological evidence of past infection | If recent exposure or immunosuppression, request HCV RNA and repeat testing |
Positive | Detected | Current HCV infection | Assess liver disease, check coinfections, refer or treat according to pathway |
Positive | Not detected | Past resolved infection or false reactive antibody | No treatment for HCV needed unless recent exposure or ongoing risk suggests repeat RNA |
Negative | Detected | Early acute infection or impaired antibody response | Repeat serology, confirm RNA, discuss with virology or microbiology |
Equivocal | Not detected | Low-level reactivity or non-specific assay signal | Repeat sample and consider risk profile |
Two reporting pitfalls recur.
The first is telling a patient they “have hepatitis C” based only on antibody. That can cause avoidable distress and incorrect coding.
The second is reassuring a high-risk recently exposed patient on the basis of a negative antibody alone. If the exposure was within the serological window period, RNA is the more useful early test.
Acute infection has a different diagnostic pattern
Acute hepatitis C is frequently asymptomatic. When symptomatic, it may present with malaise, jaundice, dark urine, right upper quadrant discomfort, or marked ALT elevation. These features overlap with hepatitis A, hepatitis B, drug-induced liver injury, Epstein-Barr virus, cytomegalovirus, autoimmune hepatitis, and biliary disease.
The most useful diagnostic clues are:
HCV RNA detected with negative or evolving antibody
Seroconversion from anti-HCV negative to positive
A marked rise in ALT with a compatible exposure history
Recent documented contact with a viraemic source
Where acute infection is suspected, discuss testing intervals with the laboratory or infectious diseases team. A single time point may not settle the diagnosis.
After needlestick injury from a known or possible HCV-positive source, UK occupational health pathways usually involve baseline testing with follow-up testing for RNA and antibody. HCV post-exposure prophylaxis is not used in the way HIV PEP is used. The aim is early detection and prompt linkage to curative treatment if infection occurs.
Genotype testing is less central than it used to be
Historically, HCV genotype drove treatment choice and duration. Genotypes 1 to 6 have different global distributions and treatment responses to older interferon-based regimens.
With current pangenotypic direct-acting antivirals, many pathways no longer require genotype before treatment. That said, genotype can still matter in selected cases, such as:
Previous treatment failure
Complex cirrhosis management
Some specialist antiviral decisions
Epidemiological investigation
Imported infections where subtype may affect resistance interpretation
Baseline viral load remains useful for documentation and treatment monitoring, although modern regimens are highly effective across a wide range of starting viral loads.
Resistance testing is not a routine diagnostic test for all newly diagnosed patients. It is usually reserved for specialist scenarios, especially after virological failure.
Core antigen has a role, but RNA remains the reference standard
HCV core antigen detects a viral protein rather than nucleic acid. It is cheaper and simpler than molecular testing in some settings, and a positive result strongly suggests active infection.
Its limitation is analytical sensitivity. Core antigen is generally less sensitive than RNA at low viral loads. For UK hospital and reference laboratory practice, RNA remains the standard confirmatory test for active infection.
Core antigen may have a place in defined pathways, especially where molecular testing access is limited. If the clinical question is high-stakes, such as early acute infection or immunocompromised infection, RNA is preferred.
Point-of-care and dried blood spot testing improve access
Not every patient who needs testing attends phlebotomy. Diagnostic strategy must account for this.
Dried blood spot testing is widely used in community drug services, prisons, outreach clinics, and some primary care settings. It allows capillary sampling and can support antibody, antigen, or RNA-based pathways depending on the assay and service model.
Point-of-care antibody tests are useful for rapid screening, but a reactive result still needs confirmation of current infection unless the point-of-care platform includes RNA testing.
These approaches matter because the highest-yield testing often occurs outside traditional outpatient clinics. A technically excellent hospital algorithm has limited value if it misses people with the highest burden of undiagnosed infection.
Special diagnostic situations need care
Immunosuppressed patients
In immunosuppressed patients, antibody responses may be delayed or absent. This includes some transplant recipients, patients receiving B-cell depleting therapy, and those with advanced immunodeficiency.
If suspicion remains despite negative serology, request HCV RNA. Do not rely on antibody alone.
Haemodialysis patients
Dialysis units require careful surveillance because of the severe consequences of healthcare-associated transmission. HCV RNA may be used more readily where exposure risk or unexplained ALT abnormalities arise. Infection prevention teams should be involved early if a new dialysis-associated case is suspected.
People living with HIV
HIV and HCV coinfection shares transmission routes and has implications for liver disease progression, antiretroviral interactions, and treatment planning. Diagnosis follows the same principles, but clinicians should maintain a lower threshold for RNA testing after recent exposure.
Pregnancy and infants
HCV antibody screening identifies exposure, but RNA confirms maternal viraemia. Vertical transmission risk is linked to maternal viraemia, not antibody positivity alone.
Infant diagnosis requires specific timing. Maternal anti-HCV antibody can persist for many months, so early antibody testing in the infant can mislead. Paediatric pathways usually rely on appropriately timed RNA testing and later serology according to local guidance.
After successful treatment
Anti-HCV antibody usually remains positive after cure. Sustained virological response is based on RNA testing after treatment completion, commonly at 12 weeks in many pathways.
A patient cured once can be reinfected. In someone with ongoing risk, antibody is not useful for detecting reinfection because it remains positive. Use HCV RNA.
Pre-analytical and reporting details change outcomes
Several practical laboratory points deserve attention.
Sample type matters. Serum or plasma is standard for antibody and RNA testing. Dried blood spot samples require validated pathways and correct collection technique.
Low-volume samples can block reflex testing. If an antibody screen returns reactive but RNA cannot be performed, the report should make the need for a further sample obvious.
Contamination control matters in molecular assays. Laboratories use physical separation, controls, and validated workflows to reduce false positives. Unexpected low-level RNA detection should be interpreted with the clinical picture and, when needed, a repeat sample.
Reports should avoid ambiguous wording. “Evidence of past exposure” is not the same as “active hepatitis C”. Good reports state whether RNA was detected and what that means for current infection.
A useful confirmed positive report should usually prompt:
Clinical review and liver fibrosis assessment
Testing for HIV and hepatitis B, if not already done
Assessment of alcohol use and metabolic liver risk
Vaccination against hepatitis A and B where appropriate
Referral or direct treatment pathway entry
Harm reduction support if ongoing transmission risk exists
Do not let liver function tests drive the diagnosis alone
Liver function tests help assess disease activity and severity, but they are poor screening tools for HCV.
A patient with chronic hepatitis C may have normal ALT. Another patient may have raised ALT due to fatty liver disease, alcohol, medication, autoimmune disease, or biliary pathology. Testing only those with abnormal liver enzymes will miss infections.
By contrast, risk-based testing and opt-out testing in higher-prevalence services detect more cases. This is reflected in UK public health approaches used in prisons, drug and alcohol services, sexual health services, and emergency departments in selected settings.
Microbiology input adds value beyond the result
The microbiologist’s role is not limited to authorising a positive RNA.
Useful input includes:
Advising on early testing after exposure
Interpreting discordant antibody and RNA results
Supporting outbreak or healthcare-associated transmission investigations
Helping services choose reflex, dried blood spot, or point-of-care pathways
Ensuring reports guide action rather than create uncertainty
Linking diagnostic algorithms with local treatment services
For example, a reactive antibody with RNA not detected in a person who injected drugs years ago may need no HCV treatment today. The same result in someone with a needle-sharing exposure two weeks ago needs repeat RNA testing. The laboratory result is identical. The clinical interpretation is not.
A practical UK diagnostic pathway
A clear pathway reduces missed cases and repeat appointments.
Test anti-HCV antibody for screening unless acute infection or immunosuppression makes RNA necessary from the start.
Reflex to HCV RNA if antibody is reactive, provided the sample and laboratory pathway allow it.
Report current infection clearly when RNA is detected, with advice for referral or treatment pathway entry.
Interpret antibody-positive and RNA-negative results carefully, especially after recent exposure or in people with ongoing risk.
Use RNA for reinfection monitoring in anyone previously antibody-positive.
Do not use ALT as a gatekeeper for testing when risk is present.
Document cure with RNA, not antibody, after treatment.
This approach aligns with the direction of UK practice: simplify testing, confirm viraemia quickly, and link infected patients to curative treatment.
The takeaway
Hepatitis C diagnosis is straightforward when each test is used for the right purpose. Anti-HCV antibody identifies exposure. HCV RNA identifies current infection. The gap between those two statements is where many diagnostic errors occur.
The best diagnostic pathways close that gap with reflex RNA testing, accessible sampling, clear reports, and clinical interpretation that accounts for timing, immune status, and ongoing risk.
For a potentially curable chronic viral infection, a precise diagnosis is more than a laboratory endpoint. It is the first step in preventing cirrhosis, reducing transmission, and moving the UK closer to hepatitis C elimination.
Comments